RXi Pharmaceuticals Corporation announced the closing of its acquisition of all of the outstanding capital stock of MirImmune Inc., a privately-held company focused on the development of next generation immunotherapies for the treatment of cancer, pursuant to that previously disclosed exclusive option agreement. To lead the Company in this effort, Alexey Eliseev, PhD has been appointed as RXi's Chief Business Officer.  In this new role, Dr. Eliseev will spearhead the business development initiatives for the Company's immunotherapy program. Dr. Eliseev is a highly accomplished leader with over 20 years of experience in academia, biotechnology industry and venture capital and most recently was the founder and CEO of MirImmune Inc.